Education
About Us
Working with TipRanks
Follow Us
Orexo AB (ORXOF)
OTHER OTC:ORXOF
ORXOF Stock Chart & Stats
$2.67
-$0.42(-28.00%)
At close: 4:00 PM EDT
$2.67
-$0.42(-28.00%)
Day’s Range― - ―
52-Week Range$1.08 - $3.38
Previous CloseN/A
Volume3.00K
Average Volume (3M)66.00
Market Cap
$92.25M
Enterprise Value$1.10B
Total Cash (Recent Filing)$121.30M
Total Debt (Recent Filing)$495.60M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Feb 05, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding34,710,640
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-4.78
Price to Sales (P/S)1.02
P/FCF Ratio-16.21
Enterprise Value/Market Cap11.96
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit2.25
Enterprise Value/Ebitda39.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $1.08 and its highest was $3.38 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $92.25M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Feb 05, 2026 which is in 50 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Oct 23, 2025. The company reported -$0.097 earnings per share for the quarter, missing the consensus estimate of -$0.054 by -$0.043.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.03.
How many shares outstanding does Orexo AB have?
Orexo AB has 34,710,640 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.097 in its last earnings report, missing expectations of -$0.054. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant R&D progress and strategic developments, such as the BARDA partnership for OX390 and positive growth in the U.S. commercial segment. However, financial challenges remain, including negative EBITDA, revenue declines in the U.S. commercial business, and market uncertainties for OX640. Despite these challenges, strategic initiatives and partnerships indicate potential for future growth.View all ORXOF earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―